Lattice Biologics Ltd. is an emerging leader in the field of cellular therapies and tissue engineering, with a focus on bone, skin, and cartilage regeneration. Lattice develops and processes biologic allograft products for domestic and international markets.
Lattice’s allograft products are used in a variety of clinical applications, including:
Potent biological scaffolds strategically control stem cell fate and function, allowing our allografts to harness the regenerative potential of patient’s own stem cells and improve surgical outcomes.
Lattice Biologics’ Next Generation Allograft Technology is made possible through the use of decellularized human Extracellular Matrix (ECM), a biological scaffold (substrate) for our allografts. This is a directed scaffold which allows us to differentiate (i.e. bone vs. skin vs. cartilage) and culture cells and harness the healing capabilities of patients’ bodies by activating their own stem cells.
Learn how Lattice Biologics’ Next Generation ECM-based Allografts are stacking the odds in patients’ favor.
Lattice is also partnered in developing new precision medicine technologies to address widespread unmet clinical needs in cancer treatment. These technologies will provide an invaluable diagnostic service by utilizing patients’ own breast cancer or solid tumor cells, amplifying them within a human Extracellular Cellular Matrix (ECM) and utilizing proprietary viability markers to test the efficacy of anti-cancer agents. The principal goal of this work is to develop diagnostic treatments capable of assisting physicians in identifying the most effective treatment plans for individuals on a completely personalized basis.
It is the Mission of Lattice Biologics to honor the gift of tissue donation by adhering to the highest standards in safety, service, and quality. Our commitment is to make patients lives better by setting the industry standards on processing and innovation while supporting the needs of healthcare providers.